Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil
Rev. Soc. Bras. Med. Trop
; 53: e20190594, 2020. tab, graf
Article
in English
| Sec. Est. Saúde SP, Coleciona SUS, LILACS
| ID: biblio-1136866
Responsible library:
BR1.1
ABSTRACT
Abstract INTRODUCTION We conducted a cost-utility analysis of available interferon-free treatments for patients with early-stage genotype 1 chronic hepatitis C based on a Brazilian public health system perspective. METHODS A Markov model was derived using a cohort of stage F0-F2 patients treated as recommended by the Brazilian national guidelines. RESULTS:
Glecaprevir plus pibrentasvir was superior to all other treatments, followed by sofosbuvir plus velpatasvir. Sofosbuvir plus daclatasvir was identified as the least cost-effective option.CONCLUSIONS:
The above findings were confirmed via probabilistic sensitivity analysis and the tested scenarios.
Full text:
Available
Collection:
National databases
/
Brazil
Health context:
Sustainable Health Agenda for the Americas
Health problem:
Goal 4: Health financing
Database:
LILACS
/
Sec. Est. Saúde SP
/
Coleciona SUS
Main subject:
Antiviral Agents
/
Hepacivirus
/
Hepatitis C, Chronic
/
Drug Therapy, Combination
Type of study:
Practice guideline
/
Health economic evaluation
/
Prognostic study
Limits:
Humans
Country/Region as subject:
South America
/
Brazil
Language:
English
Journal:
Rev. Soc. Bras. Med. Trop
Year:
2020
Document type:
Article
Institution/Affiliation country:
Universidade Federal do Paraná/BR